Huisheng Biopharmaceutical, established by Sihuan Pharmaceutical Holdings Group in 2019 and dedicated to treating diabetes and its complications, where we are the only Chinese manufacturer with full product coverage of the indications, state-of-the-art product pipeline includes multi-generation insulins, GLP- 1, SGLT-2, DPP-4, as well as oral drugs for its complications.
The research and development speed of core products leads the industry, and it has obtained dozens of patents in major countries and regions around the world. A R&D team of more than 200 people is led by senior returned scientists, covering the entire process from early research such as molecular screening and construct...
